Your browser doesn't support javascript.
loading
Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN.
Voorhees, Peter M; Rodriguez, Cesar; Reeves, Brandi; Nathwani, Nitya; Costa, Luciano J; Lutska, Yana; Bobba, Padma; Hoehn, Daniela; Pei, Huiling; Ukropec, Jon; Qi, Ming; Lin, Thomas S; Richardson, Paul G.
  • Voorhees PM; Levine Cancer Institute, Atrium Health, Charlotte, NC.
  • Rodriguez C; Department of Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC.
  • Reeves B; Division of Hematology/Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC.
  • Nathwani N; Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA.
  • Costa LJ; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
  • Lutska Y; Janssen Scientific Affairs, LLC, Horsham, PA.
  • Bobba P; Janssen Scientific Affairs, LLC, Horsham, PA.
  • Hoehn D; Janssen Scientific Affairs, LLC, Horsham, PA.
  • Pei H; Janssen Research & Development, LLC, Titusville, NJ.
  • Ukropec J; Janssen Global Medical Affairs, Horsham, PA.
  • Qi M; Janssen Research & Development, LLC, Spring House, PA; and.
  • Lin TS; Janssen Scientific Affairs, LLC, Horsham, PA.
  • Richardson PG; Dana-Farber Cancer Institute, Boston, MA.
Blood Adv ; 5(4): 1092-1096, 2021 02 23.
Article en En | MEDLINE | ID: mdl-33606004

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Mieloma Múltiple Tipo de estudio: Clinical_trials / Diagnostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Mieloma Múltiple Tipo de estudio: Clinical_trials / Diagnostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article